{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:05:59Z","timestamp":1789707959845,"version":"4.0.1"},"reference-count":221,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Basic Science Research Program through the National Research Foundation of Korea","id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"Ministry of Education","doi-asserted-by":"publisher","award":["RS-2021-NR060117"],"award-info":[{"award-number":["RS-2021-NR060117"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korea Institute of Marine Science & Technology Promotion","id":[{"id":"https:\/\/ror.org\/04cqyfy93","id-type":"ROR","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/04cqyfy93","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Ministry of Oceans and Fisheries","award":["RS-2025-02292973"],"award-info":[{"award-number":["RS-2025-02292973"]}],"id":[{"id":"https:\/\/ror.org\/00c5s4a53","id-type":"ROR","asserted-by":"crossref"}]},{"award":["RS-2025-02292973"],"award-info":[{"award-number":["RS-2025-02292973"]}],"id":[{"id":"https:\/\/ror.org\/00c5s4a53","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is now widely accepted as a complex disorder involving multiple interconnected pathological processes. Increasing evidence suggest that neuroinflammation and immune system dysregulation actively contribute to neurodegeneration, extending beyond the traditional view that the disease is driven solely by amyloid-\u03b2 (A\u03b2) and tau pathology. With the advent of studies showing anti-amyloid antibodies to have only modest effects with significant toxicity, there has been a growing interest in investigating non-amyloid non-tau (NANT) treatment approaches. This review provided a general review of small molecules for neuroinflammation-based NANT therapies in AD. We reviewed several agents that affect the brain\/immune axis, namely, kinase inhibitors (nelflamaimod and masitinib), NLRP3 inflammasome inhibitors (MCC950, selnoflast, and dapansutrile), TREM2 activators (VG-3927), gingipain inhibitors, PPAR\u03b3 activators, KCa3.1 inhibitors, and repurposed drugs such as ambroxol and cromolyn. Some common drawbacks were identified for the drugs that failed to provide their anticipated effects. It was found that they all suffered from late-stage treatment, patient heterogeneity, inadequate central nervous system penetration, and poorly designed preclinical studies. Additional translational challenges included sex-specific differences in neuroimmune responses, APOE \u03b54-associated immune dysfunction, and the need for biomarker-guided patient selection. Although immune-targeted therapies remain strongly supported by biological evidence in AD, meaningful clinical progress will likely require earlier intervention strategies guided by biomarkers and therapies capable of targeting multiple disease pathways simultaneously.<\/jats:p>","DOI":"10.3390\/molecules31183274","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:58:59Z","timestamp":1789545539000},"page":"3274","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small-Molecule NANT Therapeutics Targeting the Brain\u2013Immune Axis in Alzheimer\u2019s Disease: Mechanisms, Clinical Progress, and Translational Challenges"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6720-257X","authenticated-orcid":false,"given":"Niti","family":"Sharma","sequence":"first","affiliation":[{"name":"Lab of Aging-Related Diseases, Bionano Research Institute, Gachon University, Seongnam-si 461-701, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8123-6183","authenticated-orcid":false,"given":"Seong Soo A.","family":"An","sequence":"additional","affiliation":[{"name":"Lab of Aging-Related Diseases, Bionano Research Institute, Gachon University, Seongnam-si 461-701, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref_1","unstructured":"Alzheimer\u2019s Association (2026). 2026 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement., 22, e71345."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: The amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ibneur.2025.05.005","article-title":"Effect of neuroinflammation on the progression of Alzheimer\u2019s disease and its significant ramifications for novel anti-inflammatory treatments","volume":"18","author":"Kamila","year":"2025","journal-title":"IBRO Neurosci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100874","DOI":"10.1016\/j.cophys.2025.100874","article-title":"Unlocking therapies for neurodegeneration: Targeting mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease","volume":"47","author":"Wong","year":"2026","journal-title":"Curr. Opin. Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11011-025-01700-z","article-title":"From metabolic dysregulation to neurodegenerative pathology: The role of hyperglycemia, oxidative stress, and blood-brain barrier breakdown in T2D-driven Alzheimer\u2019s disease","volume":"40","author":"Raza","year":"2025","journal-title":"Metab. Brain Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","article-title":"Cerebrospinal fluid proteomics in patients with Alzheimer\u2019s disease reveals five molecular subtypes with distinct genetic risk profiles","volume":"4","author":"Tijms","year":"2024","journal-title":"Nat. Aging"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lo Vecchio, F., la Torre, A., Gravina, C., D\u2019Onofrio, G., and Greco, A. (2026). Molecular Mechanisms Underlying Alzheimer\u2019s Disease Pathogenesis: Comprehensive Overview. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27104651"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Miculas, D.C., Negru, P.A., Bungau, S.G., Behl, T., Hassan, S.S.U., and Tit, D.M. (2022). Pharmacotherapy Evolution in Alzheimer\u2019s Disease: Current Framework and Relevant Directions. Cells, 12.","DOI":"10.3390\/cells12010131"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100068","DOI":"10.1016\/j.tjpad.2025.100068","article-title":"Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research","volume":"12","author":"Smith","year":"2025","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): Radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"ref_12","unstructured":"ClinicTrials (2026, July 05). A Study of Donanemab (LY3002813) in Participants with Early Alzheimer\u2019s Disease (TRAILBLAZER-ALZ 2), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04437511."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_14","unstructured":"Laura Joszt, M. (2024). Biogen abandons aducanumab, pivots focus to Lecanemab for alzheimer disease. Am. J. Manag. Care, 31."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Alkhalifa, A.E., Al Mokhlf, A., Ali, H., Al-Ghraiybah, N.F., and Syropoulou, V. (2025). Anti-Amyloid Monoclonal Antibodies for Alzheimer\u2019s Disease: Evidence, ARIA Risk, and Precision Patient Selection. J. Pers. Med., 15.","DOI":"10.3390\/jpm15090437"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Behl, C. (2024). In 2024, the amyloid-cascade-hypothesis still remains a working hypothesis, no less but certainly no more. Front. Aging Neurosci., 16.","DOI":"10.3389\/fnagi.2024.1459224"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e090032","DOI":"10.1002\/alz.090032","article-title":"Drug Development","volume":"20","author":"Coskun","year":"2024","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2019.12.033","article-title":"The Alzheimer\u2019s Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease","volume":"75","author":"Stakos","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acs.biomac.2c01233","article-title":"Amyloid Protein Cross-Seeding Provides a New Perspective on Multiple Diseases In Vivo","volume":"24","author":"Ge","year":"2023","journal-title":"Biomacromolecules"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.4103\/1673-5374.386406","article-title":"Amyloid-beta and tau protein beyond Alzheimer\u2019s disease","volume":"19","author":"Abyadeh","year":"2024","journal-title":"Neural Regen. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s40001-026-03840-z","article-title":"Neuroinflammation and blood-brain barrier dysfunction in cerebral small vessel disease: Mechanisms, biomarkers, and therapeutic implications","volume":"31","author":"Luo","year":"2026","journal-title":"Eur. J. Med. Res."},{"key":"ref_22","unstructured":"Imran, A., and Hussain, G. (2023). Chief Role of Neuroinflammation and Oxidative Stress in Brain Disorders. The Role of Natural Antioxidants in Brain Disorders, Springer International Publishing."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"25424823251341870","DOI":"10.1177\/25424823251341870","article-title":"Dual impact of neuroinflammation on cognitive and motor impairments in Alzheimer\u2019s disease","volume":"9","author":"Fakorede","year":"2025","journal-title":"J. Alzheimer\u2019s Dis. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13024-015-0048-1","article-title":"Genetics ignite focus on microglial inflammation in Alzheimer\u2019s disease","volume":"10","author":"Malik","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/1567205018666211105140732","article-title":"Microglia and its Genetics in Alzheimer\u2019s Disease","volume":"18","author":"Liang","year":"2021","journal-title":"Curr. Alzheimer Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Siebner, A.S., and Uversky, V.N. (2026). Amyloid-\u03b2, Tau Protein, \u03b1-Synuclein, TDP-43, and FUS in Mixed Pathology: And Intrinsic Disorder to Rule Them All. Int. J. Mol. Sci., 27.","DOI":"10.20944\/preprints202601.2145.v2"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s40364-025-00829-4","article-title":"Bridging the barrier: Insights into blood biomarkers and therapeutic strategies targeting choroid plexus and BBB dysfunction in alzheimer\u2019s disease","volume":"13","author":"Sharma","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13024-021-00503-x","article-title":"TDP-43 Pathology in Alzheimer\u2019s Disease","volume":"16","author":"Meneses","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41419-026-08561-z","article-title":"Beyond immune privilege: The brain as a dynamic immunological interface","volume":"17","author":"Kobeissy","year":"2026","journal-title":"Cell Death Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: Structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41423-018-0176-y","article-title":"The brain-immune cells axis controls tissue specific immunopathology","volume":"16","author":"Heyner","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tins.2020.01.003","article-title":"Astrocytes and Microglia: In Sickness and in Health","volume":"43","author":"Vainchtein","year":"2020","journal-title":"Trends Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"P495","DOI":"10.1016\/j.it.2025.12.002","article-title":"Microglia in systemic neuroimmune communication: Functions beyond phagocytosis","volume":"47","author":"Powley","year":"2026","journal-title":"Trends Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Han, J., Zhang, Z., Zhang, P., Yu, Q., Cheng, Q., Lu, Z., and Zong, S. (2025). The roles of microglia and astrocytes in neuroinflammation of Alzheimer\u2019s disease. Front. Neurosci., 19.","DOI":"10.3389\/fnins.2025.1575453"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wang, T., Liu, X., Wang, X., Hua, F., and Yan, L. (2026). TREM2 and microglial immunity in Alzheimer\u2019s disease: Mechanisms, genetics, and therapeutic opportunities. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1739875"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13024-025-00812-5","article-title":"Peripheral and central neuroimmune mechanisms in Alzheimer\u2019s disease pathogenesis","volume":"20","author":"Zhang","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.3233\/JAD-221016","article-title":"Emerging Roles of Meningeal Lymphatic Vessels in Alzheimer\u2019s Disease","volume":"94","author":"Guo","year":"2023","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12979-025-00529-5","article-title":"Systemic inflammation as a central player in the initiation and development of Alzheimer\u2019s disease","volume":"22","author":"Bayraktaroglu","year":"2025","journal-title":"Immun. Ageing"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zang, X., Chen, S., Zhu, J., Ma, J., and Zhai, Y. (2022). The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases. Front. Aging Neurosci., 14.","DOI":"10.3389\/fnagi.2022.872134"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cao, Y., Tang, K., Ma, P., Zhang, R., Yang, Y., Li, T., Zhang, Y., and Peng, X. (2025). The role of peripheral innate immune cells in Alzheimer\u2019s disease progression. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1616939"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"116232","DOI":"10.1016\/j.celrep.2025.116232","article-title":"Emerging roles for innate and adaptive immunity in tauopathies","volume":"44","author":"Johnson","year":"2025","journal-title":"Cell Rep."},{"key":"ref_42","first-page":"983640","article-title":"Microglia, Alzheimer\u2019s disease, and complement","volume":"2012","author":"Crehan","year":"2012","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"M\u00fcller, L., and Di Benedetto, S. (2025). Bridging the brain and gut: Neuroimmune mechanisms of neuroinflammation and therapeutic insights. Front. Cell. Neurosci., 19.","DOI":"10.3389\/fncel.2025.1590002"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Richards, T., Perron, J.C., Patel, K., Wurpel, J., Reznik, S.E., and Schanne, F. (2023). Therapeutic Intervention of Neuroinflammatory Alzheimer Disease Model by Inhibition of Classical Complement Pathway with the Use of Anti-C1r Loaded Exosomes. Res. Sq.","DOI":"10.21203\/rs.3.rs-3399248\/v1"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13024-025-00916-y","article-title":"The complement cascade in Alzheimer\u2019s disease: Modern implications of an ancient immune protagonist","volume":"21","author":"Papavergi","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e70458","DOI":"10.1002\/alz.70458","article-title":"The Alzheimer\u2019s disease-associated complement receptor 1 variant confers risk by impacting glial phagocytosis","volume":"21","author":"Daskoulidou","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Milinkeviciute, G., and Green, K.N. (2023). Clusterin\/apolipoprotein J, its isoforms and Alzheimer\u2019s disease. Front. Aging Neurosci., 15.","DOI":"10.3389\/fnagi.2023.1167886"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Yu, Y., Wang, C., Wang, B., Wang, X., Zhao, Q., Yan, Y., and Liu, X. (2025). Clusterin Regulates the Mechanisms of Neuroinflammation and Neuronal Circuit Impairment in Alzheimer\u2019s Disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157271"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9803","DOI":"10.1038\/s41467-024-54007-5","article-title":"Complement and microglia activation mediate stress-induced synapse loss in layer 2\/3 of the medial prefrontal cortex in male mice","volume":"15","author":"Tillmon","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Giau, V.V., Wu, S.Y., Jamerlan, A., An, S.S.A., Kim, S.Y., and Hulme, J. (2018). Gut Microbiota and Their Neuroinflammatory Implications in Alzheimer\u2019s Disease. Nutrients, 10.","DOI":"10.3390\/nu10111765"},{"key":"ref_51","first-page":"136","article-title":"The Gut\u2013brain\u2013immune Triad in Neurodegeneration: An Integrated Perspective","volume":"3","author":"Chakrabarti","year":"2025","journal-title":"J. Transl. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2486518","DOI":"10.1080\/19490976.2025.2486518","article-title":"Microbial diversity and fitness in the gut\u2013brain axis: Influences on developmental risk for Alzheimer\u2019s disease","volume":"17","author":"Jamerlan","year":"2025","journal-title":"Gut Microbes"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s44400-025-00048-6","article-title":"Association between gut microbial dysbiosis and Alzheimer\u2019s disease: An umbrella review","volume":"1","author":"Kumari","year":"2025","journal-title":"npj Dement."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.nutres.2026.01.003","article-title":"The association between gut microbiota and cognitive decline: A systematic review of the literature","volume":"147","author":"Libriani","year":"2026","journal-title":"Nutr. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.4014\/jmb.2305.05009","article-title":"Association between Mild Cognitive Impairment and Gut Microbiota in Elderly Korean Patients","volume":"33","author":"Kim","year":"2023","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_56","first-page":"e70057","article-title":"A systematic review and meta-analysis of basal microbiota and cognitive function in Alzheimer\u2019s disease: A potential target for treatment or a contributor to disease progression?","volume":"16","author":"Villarino","year":"2024","journal-title":"Alzheimer\u2019s Dement. Diagn. Assess. Dis. Monit."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Cipriano, G.L., Grimaldi, A., Marra, A., Quartarone, A., and Maresca, G. (2026). Gut microbiota and cognitive decline: A scoping review of microbial mechanisms and adaptive responses in dementia. Front. Aging Neurosci., 18.","DOI":"10.3389\/fnagi.2026.1782720"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Xu, J., and Lu, Y. (2025). The microbiota-gut-brain axis and central nervous system diseases: From mechanisms of pathogenesis to therapeutic strategies. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1583562"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1097\/CM9.0000000000003695","article-title":"Adaptive immunity in the neuroinflammation of Alzheimer\u2019s disease","volume":"138","author":"Liu","year":"2025","journal-title":"Chin. Med. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e714","DOI":"10.1002\/mco2.714","article-title":"The interaction of innate immune and adaptive immune system","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1038\/s41467-025-64503-x","article-title":"Stage-specific roles of clonally expanded CD8+ T cells in regulating amyloid pathology in Alzheimer\u2019s disease models","volume":"16","author":"Ohyagi","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41593-023-01415-3","article-title":"Infiltrating CD8+ T cells exacerbate Alzheimer\u2019s disease pathology in a 3D human neuroimmune axis model","volume":"26","author":"Jorfi","year":"2023","journal-title":"Nat. Neurosci."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Duan, Z., and Cui, Y. (2023). CD8+ T cells in brain injury and neurodegeneration. Front. Cell. Neurosci., 17.","DOI":"10.3389\/fncel.2023.1281763"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"148589","DOI":"10.1016\/j.brainres.2023.148589","article-title":"Alzheimer\u2019s disease: The role of T lymphocytes in neuroinflammation and neurodegeneration","volume":"1821","author":"Asamu","year":"2023","journal-title":"Brain Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/bpa.12911","article-title":"Interaction of microglia with infiltrating immune cells in the different phases of stroke","volume":"30","author":"Berchtold","year":"2020","journal-title":"Brain Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00018-024-05533-4","article-title":"Innate and adaptive immunity in neurodegenerative disease","volume":"82","author":"Huang","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1212\/01.wnl.0000311269.57716.63","article-title":"Protective effects of NSAIDs on the development of Alzheimer disease","volume":"70","author":"Vlad","year":"2008","journal-title":"Neurology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"101729","DOI":"10.1016\/j.jsps.2023.101729","article-title":"Exploring the role of COX-2 in Alzheimer\u2019s disease: Potential therapeutic implications of COX-2 inhibitors","volume":"31","author":"Moussa","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kulesza, A., Paczek, L., and Burdzinska, A. (2023). The Role of COX-2 and PGE2 in the Regulation of Immunomodulation and Other Functions of Mesenchymal Stromal Cells. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020445"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s13311-019-00770-z","article-title":"Cyclooxygenase-2 Induced the \u03b2-Amyloid Protein Deposition and Neuronal Apoptosis Via Upregulating the Synthesis of Prostaglandin E2 and 15-Deoxy-\u039412,14-prostaglandin J2","volume":"16","author":"Guan","year":"2019","journal-title":"Neurotherapeutics"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1021\/acs.biochem.7b01019","article-title":"Molecular Mechanisms in the Selectivity of Nonsteroidal Anti-Inflammatory Drugs","volume":"57","author":"Shamsudin","year":"2018","journal-title":"Biochemistry"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"The Alzheimer\u2019s Disease Anti-inflammatory Prevention Trial Research Group (2013). Results of a follow-up study to the randomized Alzheimer\u2019s Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimer\u2019s Dement., 9, 714\u2013723.","DOI":"10.1016\/j.jalz.2012.11.012"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","article-title":"A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment","volume":"30","author":"Thal","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Germann, U.A., and Alam, J.J. (2020). P38\u03b1 MAPK signaling\u2014A robust therapeutic target for Rab5-mediated neurodegenerative disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155485"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13024-023-00663-y","article-title":"Drug development targeting degeneration of the basal forebrain cholinergic system: Its time has come","volume":"18","author":"Alam","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Falcicchia, C., Tozzi, F., Arancio, O., Watterson, D.M., and Origlia, N. (2020). Involvement of p38 MAPK in Synaptic Function and Dysfunction. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165624"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1038\/s41467-022-32944-3","article-title":"Preclinical and randomized clinical evaluation of the p38\u03b1 kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_78","unstructured":"ClinicalTrials (2026, June 11). A Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06815965."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Cast\u00e9ran, N., Borge, L., Hajem, B., Lermet, A., and Sippl, W. (2009). Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007258"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/vco.12817","article-title":"Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-\u03b1, PDGFR-\u03b2, and Lyn in canine prostate cancer cell lines","volume":"20","author":"Klose","year":"2022","journal-title":"Vet. Comp. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"173035","DOI":"10.1016\/j.ejphar.2020.173035","article-title":"Microglia and mast cells generate proinflammatory cytokines in the brain and worsen inflammatory state: Suppressor effect of IL-37","volume":"875","author":"Conti","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e1148","DOI":"10.1212\/NXI.0000000000001148","article-title":"Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial","volume":"9","author":"Vermersch","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_83","unstructured":"ClinicalTrials (2026, May 25). Efficacy and Safety of Masitinib in Combination with SoC Versus Placebo in the Treatment of ALS Patients, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07174492."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt75","article-title":"Masitinib as an adjunct therapy for mild-to-moderate Alzheimer\u2019s disease: A randomised, placebo-controlled phase 2 trial","volume":"3","author":"Piette","year":"2011","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-023-01169-x","article-title":"Masitinib for mild-to-moderate Alzheimer\u2019s disease: Results from a randomized, placebo-controlled, phase 3, clinical trial","volume":"15","author":"Dubois","year":"2023","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_86","unstructured":"ClinicalTrials (2026, May 24). Masitinib in Patients with Mild Alzheimer\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05564169."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"109941","DOI":"10.1016\/j.neuropharm.2024.109941","article-title":"NLRP3 inflammasome signalling in Alzheimer\u2019s disease","volume":"252","author":"McManus","year":"2024","journal-title":"Neuropharmacology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41423-025-01275-w","article-title":"NLRP3 inflammasome in neuroinflammation and central nervous system diseases","volume":"22","author":"Xu","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbi.2023.11.031","article-title":"MCC950 reduces autophagy and improves cognitive function by inhibiting NLRP3-dependent neuroinflammation in a rat model of Alzheimer\u2019s disease","volume":"116","author":"Naeem","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbi.2016.12.014","article-title":"Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-\u03b2 and cognitive function in APP\/PS1 mice","volume":"61","author":"Dempsey","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1007\/s12035-024-04662-y","article-title":"Therapeutic Potential of MCC950 in Restoring Autophagy and Cognitive Function in STZ-Induced Rat Model of Alzheimer\u2019s Disease","volume":"62","author":"Naeem","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Singh, S., Shaikh, I.A., More, S.S., Mahnashi, M.H., Almohaimeed, H.M., El-Sherbiny, M., Ghoneim, M.M., Umar, A., Soni, H.K., and Agrawal, H. (2022). Blockage of KHSRP-NLRP3 by MCC950 Can Reverse the Effect of Manganese-Induced Neuroinflammation in N2a Cells and Rat Brain. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113224"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"175091","DOI":"10.1016\/j.ejphar.2022.175091","article-title":"Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome","volume":"928","author":"Li","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Han, S., He, Z., Hu, X., Li, X., Zheng, K., Huang, Y., Xiao, P., Xie, Q., Ni, J., and Liu, Q. (2023). Inhibiting NLRP3 Inflammasome Activation by CY-09 Helps to Restore Cerebral Glucose Metabolism in 3\u00d7Tg-AD Mice. Antioxidants, 12.","DOI":"10.3390\/antiox12030722"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1021\/acschemneuro.2c00348","article-title":"CY-09 Alleviates the Depression-like Behaviors via Inhibiting NLRP3 Inflammasome-Mediated Neuroinflammation in Lipopolysaccharide-Induced Mice","volume":"13","author":"Wang","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"ref_98","unstructured":"ClinicalTrials (2006, May 05). Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study with Inzomelid, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04015076."},{"key":"ref_99","unstructured":"(2026, May 21). A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05924243."},{"key":"ref_100","unstructured":"(2026, May 21). A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants with Atherosclerosis at Risk for Major Adverse Cardiac Events (RIVULET), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07448038?intr=selnoflast&viewType=Card&rank=1."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"El-Sharkawy, L.Y., Brough, D., and Freeman, S. (2020). Inhibiting the NLRP3 Inflammasome. Molecules, 25.","DOI":"10.3390\/molecules25235533"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"32145","DOI":"10.1073\/pnas.2009680117","article-title":"The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer\u2019s disease","volume":"117","author":"Lonnemann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12974-026-03716-3","article-title":"Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates \u03b1-synuclein-induced progression of parkinsonism","volume":"23","author":"Luque","year":"2026","journal-title":"J. Neuroinflammation"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"A70","DOI":"10.1136\/annrheumdis-2018-EWRR2019.142","article-title":"P160\u2005The first phase 2A proof-of-concept study of a selective NLRP3 inflammasome inhibitor, dapansutrile\u2122 (OLT1177\u2122), in acute gout","volume":"78","author":"Jansen","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_105","unstructured":"ClinicalTrials (2026, May 20). A Trial to Test the Use of Dapansutrile, an Anti-Inflammatory Medication, in People with Parkinson\u2019s Disease (DAPA-PD), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07157735."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"EMMM201708689","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.phrs.2014.10.009","article-title":"Tranilast: A review of its therapeutic applications","volume":"91","author":"Darakhshan","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1117634","article-title":"Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite","volume":"310","author":"Platten","year":"2005","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e015513","DOI":"10.1161\/JAHA.119.015513","article-title":"Novel Role for Tranilast in Regulating NLRP3 Ubiquitination, Vascular Inflammation, and Atherosclerosis","volume":"9","author":"Chen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"101453","DOI":"10.1016\/j.jpha.2025.101453","article-title":"Tranilast ameliorates experimental abdominal aortic aneurysm by inhibiting the NLRP3 inflammasome pathway","volume":"16","author":"Liu","year":"2026","journal-title":"J. Pharm. Anal."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3899\/jrheum.090769","article-title":"CXCL 9 and CXCL 10 as Sensitive Markers of Disease Activity in Patients with Rheumatoid Arthritis","volume":"37","author":"Kuan","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.bcp.2011.06.013","article-title":"Suppression of human CD4+ T cell activation by 3, 4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10","volume":"82","author":"Hertenstein","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/rheumatology\/kem160","article-title":"The anti-allergic drug, N-(3\u2032, 4\u2032-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis","volume":"46","author":"Inglis","year":"2007","journal-title":"Rheumatology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Wang, S., Yu, L., Yang, H., Li, C., Hui, Z., Xu, Y., and Zhu, X. (2016). Oridonin Attenuates Synaptic Loss and Cognitive Deficits in an A\u03b21\u201342-Induced Mouse Model of Alzheimer\u2019s Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151397"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1002\/ptr.70185","article-title":"Oridonin Ameliorates Alzheimer\u2019s Disease-Like Pathology in Male Mice Through Inhibition of Receptor-Interacting Protein Kinase 1","volume":"40","author":"Li","year":"2026","journal-title":"Phytother. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41401-022-00995-3","article-title":"Oridonin ameliorates caspase-9-mediated brain neuronal apoptosis in mouse with ischemic stroke by inhibiting RIPK3-mediated mitophagy","volume":"44","author":"Li","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/acschemneuro.7b00124","article-title":"Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis","volume":"8","author":"Guo","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.chembiol.2017.08.011","article-title":"Boron-Based Inhibitors of the NLRP3 Inflammasome","volume":"24","author":"Baldwin","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Haque, I., Thapa, P., Burns, D.M., Zhou, J., Sharma, M., Sharma, R., and Singh, V. (2024). NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202405.0668.v1"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13024-023-00609-4","article-title":"Insights from new in vivo models of TREM2 variants","volume":"18","author":"Jain","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e70586","DOI":"10.1002\/alz.70586","article-title":"The TREM2 H157Y variant is associated with more severe neurodegeneration in Alzheimer\u2019s disease and altered immune-related processes","volume":"21","author":"Tsui","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer\u2019s disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","article-title":"TREM2\u2014A key player in microglial biology and Alzheimer disease","volume":"14","author":"Ulland","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Yang, H., Kim, D., Yang, Y., Bagyinszky, E., and An, S.S.A. (2025). TREM2 in Neurodegenerative Disorders: Mutation Spectrum, Pathophysiology, and Therapeutic Targeting. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157057"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Nada, H., Yuan, S., Gaamouch, F.E., Cho, S., and Gabr, M.T. (2026). Small Molecule Agonists of TREM2 Reprogram Microglia and Protect Synapses in Human Alzheimer\u2019s Models. bioRxiv.","DOI":"10.64898\/2026.01.19.700278"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.14283\/jpad.2024.164","article-title":"Roles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer\u2019s Disease","volume":"11","author":"Lin","year":"2024","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1021\/acsmedchemlett.5c00299","article-title":"Discovery of a Small Molecule TREM2 Agonist with Improved In Vitro Pharmacokinetic Profile and Validated Target Engagement","volume":"16","author":"Yuan","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_129","unstructured":"(2026, May 23). A Phase 1 Study of VG-3927 in Healthy Adults and Patients with Alzheimer\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06343636?intr=VG-3927&viewType=Card&rank=1."},{"key":"ref_130","unstructured":"Mirescu, C., and Kaufmann, P. (2025, January 1\u20135). Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations. Proceedings of the AD\/PD\u2122 2025 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases, Vienna, Austria."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"E298","DOI":"10.1152\/ajpendo.00124.2025","article-title":"Synergistic potential of TREM2 agonists and exercise training in Alzheimer\u2019s disease","volume":"330","author":"Zhang","year":"2026","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Ma, Y.N., Hu, X., Karako, K., Song, P., Tang, W., and Xia, Y. (2025). The potential and challenges of TREM2-targeted therapy in Alzheimer\u2019s disease: Insights from the INVOKE-2 study. Front. Aging Neurosci., 17.","DOI":"10.3389\/fnagi.2025.1576020"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.hlife.2026.03.001","article-title":"Porphyromonas gingivalis links Alzheimer\u2019s disease and periodontal disease: Neuroinflammatory mechanisms and therapeutic implications","volume":"4","author":"Jin","year":"2026","journal-title":"hLife"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Shawkatova, I., Durmanova, V., and Javor, J. (2025). Alzheimer\u2019s Disease and Porphyromonas gingivalis: Exploring the Links. Life, 15.","DOI":"10.3390\/life15010096"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"eaau3333","DOI":"10.1126\/sciadv.aau3333","article-title":"Porphyromonas gingivalis in Alzheimer\u2019s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors","volume":"5","author":"Dominy","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/13543784.2022.2117605","article-title":"COR388 (atuzaginstat): An investigational gingipain inhibitor for the treatment of Alzheimer disease","volume":"31","author":"Sabbagh","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_137","unstructured":"(2026, May 12). GAIN Trial: Phase 2\/3 Study of COR388 in Subjects with Alzheimer\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03823404?intr=cor388&viewType=Card&rank=3&tab=results."},{"key":"ref_138","unstructured":"(2026, May 22). Study of LHP588 in Subjects with P. Gingivalis-Positive Alzheimer\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06847321."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/cpdd.1391","article-title":"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants","volume":"13","author":"Li","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Nicolakakis, N., and Hamel, E. (2010). The Nuclear Receptor PPAR\u03b3 as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer\u2019s Disease. Front. Aging Neurosci., 2.","DOI":"10.3389\/fnagi.2010.00021"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2010675","DOI":"10.1155\/2018\/2010675","article-title":"Signaling Mechanisms of Selective PPAR\u03b3 Modulators in Alzheimer\u2019s Disease","volume":"2018","author":"Govindarajulu","year":"2018","journal-title":"PPAR Res."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Galanou, O.N., and Konstandi, M. (2025). Unraveling the Function of PPAR\u03b1 in Neurodegenerative Disorders: A Potential Pathway to Novel Therapies. Biomedicines, 13.","DOI":"10.3390\/biomedicines13112813"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"100979","DOI":"10.1016\/j.nexres.2025.100979","article-title":"Brain insulin resistance as an early target to attenuate neuroinflammation, oxidative stress and proteinopathies in Alzheimer\u2019s disease: A systematic review of five natural products","volume":"2","author":"Mohamed","year":"2025","journal-title":"Next Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1038\/srep09000","article-title":"Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer\u2019s disease","volume":"5","author":"Chang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1345\/aph.1Q238","article-title":"Rosiglitazone and pioglitazone for the treatment of Alzheimer\u2019s disease","volume":"45","author":"Miller","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate Alzheimer\u2019s disease: Results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1474-4422(21)00043-0","article-title":"Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer\u2019s disease (TOMMORROW): A prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Burns","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.2147\/DDDT.S367229","article-title":"Protective effects of pioglitazone on cognitive impairment and the underlying mechanisms: A review of literature","volume":"16","author":"Alhowail","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"eabc0555","DOI":"10.1126\/scitranslmed.abc0555","article-title":"The brain penetrant PPAR\u03b3 agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy","volume":"13","author":"Vilalta","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e200034","DOI":"10.1212\/NXG.0000000000200034","article-title":"Efficacy and Safety of Leriglitazone in Patients with Friedreich Ataxia: A Phase 2 Double-Blind, Randomized Controlled Trial (FRAMES)","volume":"8","author":"Pandolfo","year":"2022","journal-title":"Neurol. Genet."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1474-4422(22)00495-1","article-title":"Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): A randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial","volume":"22","author":"Engelen","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Pizcueta, P., Vergara, C., Emanuele, M., Vilalta, A., Rodr\u00edguez-Pascau, L., and Martinell, M. (2023). Development of PPAR\u03b3 Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043201"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"105162","DOI":"10.1016\/j.nbd.2020.105162","article-title":"PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia","volume":"148","author":"Britti","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1093\/brain\/awae169","article-title":"Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy","volume":"147","author":"Golse","year":"2024","journal-title":"Brain"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"108193","DOI":"10.1016\/j.phrs.2026.108193","article-title":"PPAR\u03b3 activation by leriglitazone counteracts neurodegeneration and neuroinflammation in a disease-relevant mouse model of COASY dysfunction","volume":"227","author":"Cavestro","year":"2026","journal-title":"Pharmacol. Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4093\/dmj.2020.0272","article-title":"Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus","volume":"45","author":"Bae","year":"2021","journal-title":"Diabetes Metab. J."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-023-01841-4","article-title":"Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: A nationwide nested case-control study","volume":"22","author":"Yoo","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4093\/dmj.2021.0264","article-title":"A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab. J."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1111\/dom.16625","article-title":"Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial","volume":"27","author":"Hong","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"104030","DOI":"10.1016\/j.mcn.2025.104030","article-title":"Neuroprotective effect of the peroxisome proliferator-activated receptor \u03b3 agonist lobeglitazone following intracerebral hemorrhage in rats","volume":"134","author":"Kim","year":"2025","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.brainresbull.2021.05.011","article-title":"Effect of lobeglitazone on motor function in rat model of Parkinson\u2019s disease with diabetes co-morbidity","volume":"173","author":"Hassanzadeh","year":"2021","journal-title":"Brain Res. Bull."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1021\/jm070663s","article-title":"Novel inhibitors of the Gardos channel for the treatment of sickle cell disease","volume":"51","author":"Burns","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_163","first-page":"868972","article-title":"Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer\u2019s Disease","volume":"2012","author":"Maezawa","year":"2012","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Lin, Y., Zhao, Y.J., Zhang, H.L., Hao, W.J., Zhu, R.D., Wang, Y., Hu, W., and Zhou, R.P. (2022). Regulatory role of KCa3.1 in immune cell function and its emerging association with rheumatoid arthritis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.997621"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1523\/JNEUROSCI.3593-06.2007","article-title":"The Ca2+-activated K+ channel KCNN4\/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration","volume":"27","author":"Kaushal","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s11064-017-2223-y","article-title":"Senicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke","volume":"42","author":"Staal","year":"2017","journal-title":"Neurochem. Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12975-023-01152-6","article-title":"Repurposing the KCa3.1 Blocker Senicapoc for Ischemic Stroke","volume":"15","author":"Lee","year":"2024","journal-title":"Transl. Stroke Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/acn3.754","article-title":"Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer\u2019s disease","volume":"6","author":"Jin","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_169","unstructured":"(2026, May 21). Senicapoc in Alzheimer\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04804241."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Reading, C.L., Yan, J., Testa, M.A., Simonson, D.C., Javaid, H., Schmunk, L., Martin-Herranz, D.E., Brooke, R., Gordevicius, J., and Zhang, J. (2025). An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer\u2019s disease. Front. Neurosci., 19.","DOI":"10.3389\/fnins.2025.1516746"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.coph.2009.07.004","article-title":"Cellular mechanisms of insulin resistance: Role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation","volume":"9","author":"Tanti","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/nmt-2021-0022","article-title":"NM101 Phase III study of NE3107 in Alzheimer\u2019s disease: Rationale, design and therapeutic modulation of neuroinflammation and insulin resistance","volume":"11","author":"Reading","year":"2021","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e39027","DOI":"10.1097\/MD.0000000000039027","article-title":"A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias","volume":"103","author":"Haroon","year":"2024","journal-title":"Medicine"},{"key":"ref_174","unstructured":"BioVie (2026, June 20). SUNRISE-PD to Evaluate the Effect of Bezisterim (NE3107) on Motor and Non-Motor Symptoms in ~60 Patients with Parkinson\u2019s Disease Who Are Na\u00efve to Carbidopa\/Levodopa. Available online: https:\/\/feeds.issuerdirect.com\/news-release.html?newsid=7665684946168728."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"Maor","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1111\/bph.14618","article-title":"Microglial inflammation and phagocytosis in Alzheimer\u2019s disease: Potential therapeutic targets","volume":"176","author":"Nizami","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Lu, R., Zhang, L., and Yang, X. (2022). Interaction between autophagy and the NLRP3 inflammasome in Alzheimer\u2019s and Parkinson\u2019s disease. Front. Aging Neurosci., 14.","DOI":"10.3389\/fnagi.2022.1018848"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Zhou, W., Xiao, D., Zhao, Y., Tan, B., Long, Z., Yu, L., and He, G. (2021). Enhanced Autolysosomal Function Ameliorates the Inflammatory Response Mediated by the NLRP3 Inflammasome in Alzheimer\u2019s Disease. Front. Aging Neurosci., 13.","DOI":"10.3389\/fnagi.2021.629891"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.4103\/NRR.NRR-D-23-01664","article-title":"Ambroxol, the cough expectorant with neuroprotective effects","volume":"19","author":"Patzwaldt","year":"2024","journal-title":"Neural Regen. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e21967","DOI":"10.1002\/syn.21967","article-title":"Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate","volume":"71","author":"Ko","year":"2017","journal-title":"Synapse"},{"key":"ref_181","first-page":"100096","article-title":"Ambroxol: A potential therapeutics against neurodegeneration","volume":"7","author":"Dhanve","year":"2023","journal-title":"Health Sci. Rev."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of \u03b2-glucocerebrosidase reduces pathological \u03b1-synuclein and restores lysosomal function in Parkinson\u2019s patient midbrain neurons","volume":"36","author":"Mazzulli","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Chwiszczuk, L.J., Breitve, M.H., Kirsebom, B.B., Selnes, P., Fl\u00f8vig, J.C., Knapskog, A.B., Skogseth, R.E., Hubbers, J., Holst-Larsen, E., and Rongve, A. (2023). The ANeED study\u2014Ambroxol in new and early dementia with Lewy bodies (DLB): Protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial. Front. Aging Neurosci., 15.","DOI":"10.3389\/fnagi.2023.1163184"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the Treatment of Patients with Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Silveira, C.R., MacKinley, J., Coleman, K., Li, Z., Finger, E., Bartha, R., Morrow, S., Wells, J., Borrie, M., and Tirona, R. (2019). Ambroxol as a novel disease-modifying treatment for Parkinson\u2019s disease dementia: Protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol., 19.","DOI":"10.1186\/s12883-019-1252-3"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00415-026-13683-7","article-title":"Protocol of ASPro-PD: A phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson\u2019s disease","volume":"273","author":"Toffoli","year":"2026","journal-title":"J. Neurol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1038\/s41598-021-85702-8","article-title":"Cromolyn inhibits the secretion of inflammatory cytokines by human microglia (HMC3)","volume":"11","author":"Wang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Sinniah, A., Yazid, S., and Flower, R.J. (2017). The anti-allergic cromones: Past, present, and future. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00827"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.celrep.2017.10.109","article-title":"iPSC-based compound screening and in vitro trials identify a synergistic anti-amyloid \u03b2 combination for Alzheimer\u2019s disease","volume":"21","author":"Kondo","year":"2017","journal-title":"Cell Rep."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41598-018-19641-2","article-title":"Cromolyn reduces levels of the Alzheimer\u2019s disease-associated amyloid \u03b2-protein by promoting microglial phagocytosis","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1074\/jbc.M114.586602","article-title":"A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid \u03b2 in the brain in a transgenic model of Alzheimer disease","volume":"290","author":"Hori","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3233\/JAD-201419","article-title":"Evaluation of fluorinated cromolyn derivatives as potential therapeutics for Alzheimer\u2019s disease","volume":"80","author":"Shoup","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_193","unstructured":"(2026, May 21). Randomized I\/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer\u2019s Disease and Normal Healthy Volunteers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04570644?intr=cromolyn%20&viewType=Card&page=2&rank=18."},{"key":"ref_194","first-page":"1225","article-title":"Design and synthesis of highly selective brain penetrant p38\u03b1 mitogen-activated protein kinase inhibitors","volume":"65","author":"Martorelli","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1742-2094-4-21","article-title":"A novel p38 \u03b1 MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer\u2019s disease mouse model","volume":"4","author":"Munoz","year":"2007","journal-title":"J. Neuroinflammation"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"100826","DOI":"10.1016\/j.bbih.2024.100826","article-title":"A small molecule p38\u03b1 MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologies","volume":"40","author":"Frazier","year":"2024","journal-title":"Brain Behav. Immun. Health"},{"key":"ref_197","unstructured":"ClinicalTrials (2026, June 25). MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer\u2019s Disease (SKI-AD), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05194163."},{"key":"ref_198","unstructured":"Minorux Therapeutics (2026, June 22). Minoryx\u2019s Preclinical Data for Leriglitazone in Friedreich\u2019s Ataxia Published in Neurobiology of Disease Journal. Available online: http:\/\/minoryx.com\/media\/minoryx%E2%80%99s_preclinical_data_for_leriglitazone_in_friedreich%E2%80%99s_ataxia_published_in_neurobiology_of_disease_journal\/."},{"key":"ref_199","unstructured":"ClinicalTrials (2026, May 13). A Study of NE3107 in Early Parkinson\u2019s (SUNRISE-PD), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06757010?intr=HE3286%20OR%20NE3107&viewType=Card&rank=2."},{"key":"ref_200","unstructured":"(2026, May 12). A Phase 3 Study of NE3107 in Probable Alzheimer\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04669028?intr=HE3286%20OR%20NE3107&viewType=Card&rank=4."},{"key":"ref_201","unstructured":"(2026, May 22). A Single and Multiple Ascending Dose Study of COR588, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04920903?intr=COR588&viewType=Card&rank=1."},{"key":"ref_202","unstructured":"Quince Therapeutics (2026, June 22). Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588. Available online: https:\/\/ir.quincetx.com\/news-releases\/news-release-details\/cortexyme-expands-proprietary-development-pipeline-initiation."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12974-016-0620-9","article-title":"Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis","volume":"13","author":"Trias","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_204","first-page":"P273","article-title":"O4-11-03: A Proinflammatory Endophenotype Predicts Treatment Response in a Multicenter Trial of NSAIDS in AD","volume":"10","author":"Rissman","year":"2014","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/jgs.19411","article-title":"Long-term exposure to non-steroidal anti-inflammatory medication in relation to dementia risk","volume":"73","author":"Stricker","year":"2025","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Imbimbo, B.P., Solfrizzi, V., and Panza, F. (2010). Are NSAIDs useful to treat Alzheimer\u2019s disease or mild cognitive impairment?. Front. Aging Neurosci., 2.","DOI":"10.3389\/fnagi.2010.00019"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2174\/138161208784480171","article-title":"Cyclooxygenase-1 and-2 in the different stages of Alzheimer\u2019s disease pathology","volume":"14","author":"Hoozemans","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/85525","article-title":"Imaging of amyloid-\u03b2 deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy","volume":"7","author":"Bacskai","year":"2001","journal-title":"Nat. Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/aje\/kwi029","article-title":"Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia","volume":"161","author":"Gussekloo","year":"2005","journal-title":"Am. J. Epidemiol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"e90633","DOI":"10.7554\/eLife.90633","article-title":"Lost in translation: Inconvenient truths on the utility of mouse models in Alzheimer\u2019s disease research","volume":"13","author":"Granzotto","year":"2024","journal-title":"eLife"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"eadp7047","DOI":"10.1126\/scitranslmed.adp7047","article-title":"Human myelinated brain organoids with integrated microglia as a model for myelin repair and remyelinating therapies","volume":"17","author":"Lange","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"ref_212","unstructured":"Valarmathi, M.T. (2026). Patient-Derived Brain Organoids as Translational Platforms for Regenerating the Degenerating Brain: Bridging Bench Models to Clinical Therapies. Advancements in Stem Cell Treatments, IntechOpen."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Mervosh, N., and Devi, G. (2025). Estrogen, menopause, and Alzheimer\u2019s disease: Understanding the link to cognitive decline in women. Front. Mol. Biosci., 12.","DOI":"10.3389\/fmolb.2025.1634302"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e70139","DOI":"10.1002\/trc2.70139","article-title":"Sex differences and the role of estrogens in the immunological underpinnings of Alzheimer\u2019s disease","volume":"11","author":"Price","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"e199832","DOI":"10.1172\/JCI199832","article-title":"Women\u2019s midlife: The front line of Alzheimer prevention","volume":"136","author":"Mosconi","year":"2026","journal-title":"J. Clin. Investig."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5498\/wjp.v11.i8.412","article-title":"Menopause and cognitive impairment: A narrative review of current knowledge","volume":"11","author":"Conde","year":"2021","journal-title":"World J. Psychiatry"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"101594","DOI":"10.1016\/j.smim.2022.101594","article-title":"APOE mediated neuroinflammation and neurodegeneration in Alzheimer\u2019s disease","volume":"59","author":"Parhizkar","year":"2022","journal-title":"Semin. Immunol."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Dias, D., Portugal, C.C., Relvas, J., and Socodato, R. (2025). From Genetics to Neuroinflammation: The Impact of ApoE4 on Microglial Function in Alzheimer\u2019s Disease. Cells, 14.","DOI":"10.3390\/cells14040243"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00011-025-02016-5","article-title":"APOE4 impairs autophagy and A\u03b2 clearance by microglial cells","volume":"74","author":"Bassal","year":"2025","journal-title":"Inflamm. Res."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Roveta, F., Bonino, L., Piella, E.M., Rainero, I., and Rubino, E. (2024). Neuroinflammatory Biomarkers in Alzheimer\u2019s Disease: From Pathophysiology to Clinical Implications. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252211941"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10571-026-01671-4","article-title":"The Immuno-Glial Connectome in Alzheimer\u2019s Disease: Integrating Central and Peripheral Inflammatory Networks","volume":"46","author":"Gopalakrishna","year":"2026","journal-title":"Cell. Mol. Neurobiol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/18\/3274\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:25:21Z","timestamp":1789705521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/18\/3274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":221,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["molecules31183274"],"URL":"https:\/\/doi.org\/10.3390\/molecules31183274","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}